Bard To Join Carotid Stent Fray In 2005 With IDE Trial
This article was originally published in The Gray Sheet
Executive Summary
Bard's decision to enter the carotid stent race in 2005 reflects the firm's confidence that it will become a top player in the emerging field
You may also be interested in...
Bard Bullish On 2005 Surgical Urology Sales; Tegress To Launch Mid-Year
Bard says a 43% rise in sales of surgical stress urinary incontinence offerings such as the Contigen collagen-based injectable implant helped Q4 urology revenue grow 14% to $130.4 mil
Bard Bullish On 2005 Surgical Urology Sales; Tegress To Launch Mid-Year
Bard says a 43% rise in sales of surgical stress urinary incontinence offerings such as the Contigen collagen-based injectable implant helped Q4 urology revenue grow 14% to $130.4 mil
CMS Backs Limited Carotid Stent Coverage Expansion, Mulls Criteria For Docs
CMS is soliciting comments on standards and evaluation criteria for physicians and facilities performing carotid artery stenting procedures (CAS)